Triazolobenzodiazepines specifically inhibit PAF-induced platelet aggregation, providing a tool to study PAF-mediated biochemical mechanisms.
Answers are grounded in this paper and cite their sources.
Triazolobenzodiazepines should not alter clinical antiplatelet practice; extends in vitro tools for probing PAF platelet signaling.
Platelet-activating factor (PAF), a naturally occurring phospholipid, is a potent activator of various biological processes, including platelet aggregation. The mechanisms by which PAF acts are largely unknown, partly because of the lack of specific inhibitors for PAF-elicited responses. It was found that in washed human platelets the psychotropic triazolobenzodiazepine drugs alprazolam and triazolam potently inhibited PAF-induced changes in shape, aggregation, and secretion. The effects were specific for PAF activation, since the responses of human platelets to adenosine diphosphate, thrombin, epinephrine, collagen, arachidonate, and the calcium ionophore A23187 were not inhibited by the triazolobenzodiazepines. These psychotropic drugs should be useful in investigating the possibility that PAF or PAF-like phospholipids play a role in neuronal function and in elucidating biochemical mechanisms activated specifically by PAF in a variety of cells.
No takes yet. Share an insight, caveat, or question.
Kornecki et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: